Merck Management

Management criteria checks 3/4

Merck's CEO is Rob Davis, appointed in Apr 2021, has a tenure of 3.5 years. total yearly compensation is $20.27M, comprised of 7.9% salary and 92.1% bonuses, including company stock and options. directly owns 0.014% of the company’s shares, worth $37.86M. The average tenure of the management team and the board of directors is 3.8 years and 5.1 years respectively.

Key information

Rob Davis

Chief executive officer

US$20.3m

Total compensation

CEO salary percentage	7.9%
CEO tenure	3.5yrs
CEO ownership	0.01%
Management average tenure	3.8yrs
Board average tenure	5.1yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Rob Davis's remuneration changed compared to Merck's earnings?
Date	Total Compensation	Salary	Company Earnings
Jun 30 2024	n/a	n/a	US$14b
Mar 31 2024	n/a	n/a	US$2b
Dec 31 2023	US$20m	US$2m	US$365m
Sep 30 2023	n/a	n/a	US$5b
Jun 30 2023	n/a	n/a	US$3b
Mar 31 2023	n/a	n/a	US$13b
Dec 31 2022	US$19m	US$2m	US$15b
Sep 30 2022	n/a	n/a	US$15b
Jun 30 2022	n/a	n/a	US$17b
Mar 31 2022	n/a	n/a	US$14b
Dec 31 2021	US$14m	US$1m	US$12b
Sep 30 2021	n/a	n/a	US$6b
Jun 30 2021	n/a	n/a	US$4b
Mar 31 2021	n/a	n/a	US$5b
Dec 31 2020	US$7m	US$1m	US$5b
Sep 30 2020	n/a	n/a	US$9b
Jun 30 2020	n/a	n/a	US$9b
Mar 31 2020	n/a	n/a	US$9b
Dec 31 2019	US$8m	US$1m	US$6b
Sep 30 2019	n/a	n/a	US$9b
Jun 30 2019	n/a	n/a	US$9b
Mar 31 2019	n/a	n/a	US$8b
Dec 31 2018	US$7m	US$1m	US$6b
Sep 30 2018	n/a	n/a	US$3b
Jun 30 2018	n/a	n/a	US$1b
Mar 31 2018	n/a	n/a	US$2b
Dec 31 2017	US$6m	US$1m	US$2b

Compensation vs Market: Rob's total compensation ($USD20.27M) is above average for companies of similar size in the PE market ($USD5.82M).

Compensation vs Earnings: Rob's compensation has been consistent with company performance over the past year.

CEO

Rob Davis (57 yo)

3.5yrs

Tenure

US$20,273,287

Compensation

Mr. Robert M. Davis, also known as Rob, J. D., is Chief Executive Officer and Director at Merck & Co., Inc. since July 1, 2021 and is Chairman from December 01, 2022. He serves as President at Merck & Co.,...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Robert Davis	Chairman	3.5yrs	US$20.27m	0.014% $ 37.9m
Caroline Litchfield	Executive VP & CFO	3.5yrs	US$8.30m	0.0020% $ 5.5m
Richard DeLuca	Executive VP & President of Merck Animal Health	13.1yrs	US$6.20m	0.0060% $ 16.5m
Sanat Chattopadhyay	Executive VP & President of Merck Manufacturing Division	14.9yrs	US$6.24m	0.0062% $ 17.1m
Dean Li	Executive VP & President of Merck Research Laboratories	6.9yrs	US$9.78m	0.0018% $ 5.0m
Dalton Smart	Senior VP of Finance	less than a year	no data	0.00017% $ 468.4k
David Williams	Executive VP and Chief Information & Digital Officer	no data	no data	0.00078% $ 2.1m
Peter Dannenbaum	Vice President of Investor Relations	5.2yrs	no data	no data
Jennifer Zachary	Executive VP & General Counsel	6.5yrs	US$5.90m	0.0011% $ 3.2m
Cristal Downing	Executive VP and Chief Communications & Public Affairs Officer	3.2yrs	no data	no data
Betty Larson	Executive VP & Chief Human Resources Officer	less than a year	no data	no data
Johannes Oosthuizen	Senior VP & President Merck U.S. Human Health	3.8yrs	no data	0.00094% $ 2.6m

3.8yrs

Average Tenure

56yo

Average Age

Experienced Management: MRK's management team is considered experienced (3.8 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Robert Davis	Chairman	3.3yrs	US$20.27m	0.014% $ 37.9m
Pamela Craig	Independent Director	9.1yrs	US$400.00k	0.000070% $ 192.9k
Patricia Russo	Independent Director	29.1yrs	US$360.00k	0.00052% $ 1.4m
Thomas Glocer	Independent Lead Director	16.9yrs	US$430.10k	0.00020% $ 551.1k
Risa Lavizzo-Mourey	Independent Director	4.4yrs	US$365.00k	0.000040% $ 110.2k
Douglas Baker	Independent Director	2.4yrs	US$347.64k	0.000040% $ 110.2k
Inge Thulin	Independent Director	6.6yrs	US$340.00k	0% $ 0
Stephen Mayo	Independent Director	3.6yrs	US$350.00k	0% $ 0
Kathy Warden	Independent Director	4.6yrs	US$350.00k	0.000020% $ 55.1k
Christine Seidman	Independent Director	4.6yrs	US$350.00k	0% $ 0
Paul Rothman	Independent Director	9.1yrs	US$380.00k	0% $ 0
Mary Coe	Independent Director	5.6yrs	US$342.36k	0% $ 0

5.1yrs

Average Tenure

65.5yo

Average Age

Experienced Board: MRK's board of directors are considered experienced (5.1 years average tenure).

Merck Management

Management criteria checks 3/4

Key information

Recent management updates

Insufficient new directors

Recent updates

Merck Announces the Presentation of Positive Results from the Phase 2B/3 Clinical Trial (Mk-1654-004) Evaluating Clesrovimab

Merck’s CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) Demonstrates Positive Immune Responses in Adults with Increased Risk for Pneumococcal Disease

Merck & Co., Inc. to Report Q3, 2024 Results on Oct 31, 2024

FDA Approves Merck's KEYTRUDA® (pembrolizumab) Plus Pemetrexed and Platinum Chemotherapy as First-Line Treatment for Adult Patients with Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma

Merck Announces Overall Survival Results from the Final Analysis of the Phase 3 Keynote-811 Trial Evaluating Keytruda® (Pembrolizumab)

Upcoming dividend of US$0.77 per share

Merck Announces WINREVAIR (Sotatercept) Is Authorized for Use in Canada for Adults with Pulmonary Arterial Hypertension

Merck & Co., Inc. and EyeBio Announce Initiation of Phase 2b/3 Clinical Trial for Restoret™? for the Treatment of Diabetic Macular Edema

European Commission Approves Merck's KEYTRUDA (Pembrolizumab) Plus Padcev (Enfortumab Vedotin-Ejfv) as First-Line Treatment of Unresectable or Metastatic Urothelial Carcinoma in Adults

Merck & Co., Inc. Provides Update on Phase 3 KEYNOTE-867 and KEYNOTE-630 Trials

Merck Receives European Commission Approval for Winrevair (Sotatercept) in Combination with Other Pulmonary Arterial Hypertension (Pah) Therapies, for the Treatment of Pah in Adult Patients with Functional Class II-III

Health Canada Approves Merck's KEYTRUDA® for the Treatment of Adult Patients with Unresectable Locally Advanced or Metastatic Urothelial Cancer with No Prior Systemic Therapy for mUC, in Combination with Enfortumab Vedotin

Merck & Co., Inc. Provides Update on Phase 3 KeyVibe-008 Trial Evaluating an Investigational Fixed-Dose Combination of Vibostolimab and Pembrolizumab in Patients With Extensive-Stage Small Cell Lung Cancer

New minor risk - Share price stability

Daiichi Sankyo and Merck Announces IDeate-Lung02 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Patients with Relapsed Small Cell Lung Cancer

Merck & Co., Inc. Revises Earnings Guidance for the Year 2024

Insufficient new directors

Second quarter 2024 earnings released: EPS: US$2.14 (vs US$2.35 loss in 2Q 2023)

First quarter dividend of US$0.77 announced

Merck Receives Positive Eu Chmp Opinion for Keytruda® (Pembrolizumab) PPlus Padcev® (enfortumab vedotin-ejfv) as First-Line Treatment for Patients With Unresectable or Metastatic Urothelial Carcinoma

Merck Announces Topline Results from Phase 2b/3 Trial of Clesrovimab (MK-1654), an Investigational Respiratory Syncytial Virus Preventative Monoclonal Antibody for Infants

Merck & Co., Inc. (NYSE:MRK) completed the acquisition of Eyebiotech Limited.

Merck & Co., Inc.(NYSE:MRK) dropped from Russell 3000E Value Index

Merck Receives Positive EU CHMP Opinion for WINREVAIR (Sotatercept) in Pulmonary Arterial Hypertension (PAH)

CDC’S ACIP Unanimously Recommends Merck’s CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal Vaccination in Appropriate Adults

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age